A Phase I Study of LOXO-292 in Patients with Advanced Solid Tumors


Full Title

A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001)


LOXO-292 is an investigational drug designed to inhibit cancer growth by blocking a protein called RET. In this study, researchers are determining the highest dose of LOXO-292 that can be given in patients with solid tumors that have increased RET activity, including non-small cell lung cancer and medullary thyroid cancer. LOXO-292 is a capsule that is taken orally (by mouth).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have an advanced solid tumor that demonstrates increased RET activity, due to a RET mutation or RET fusion.
  • Patients must recover from the serious side effects of prior therapies before entering the study.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Alexander Drilon at 646-888-4206.